NeuroOne Medical Technologies Corporation (NMTC) Free cash flow
- Free cash flow · 12 months (USD): Value $-7.16M; Formula and calculation Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30..
- Price / free cash flow · 12 months: Value (m); Formula and calculation Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30..
- Free cash flow yield · 12 months: Value (m); Formula and calculation (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30..
- Free cash flow margin · 12 months: Value -75.63%; Formula and calculation (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30..
Free cash flow
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Free cash flow · 12 months (USD) | $-7.16M | Operating cash flow minus capital spending; distinct from the saved levered FCF quote figure. Period ending 2026-06-30. $-7.05M − $109.54K ≈ $-7.16M |
| Price / free cash flow · 12 months | (m) | Market cap / trailing-year free cash flow; inverse of FCF yield before percent scaling. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow yield · 12 months | (m) | (Operating cash flow − capital spending) / current market cap. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Free cash flow margin · 12 months | -75.63% | (Operating cash flow − capital spending) / revenue. Period ending 2026-06-30. $-7.16M ÷ $9.47M × 100 ≈ -75.63% |
| Free cash flow per share · 12 months | (m) | (Trailing-year operating cash flow − capital spending) / reported quarter-end common shares. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Operating cash flow · 12 months | $-7.05M | Cash generated by operating activities. Period ending 2026-06-30. |
| Operating cash flow / net income · 12 months | 0.95× | Operating cash flow / net income. Period ending 2026-06-30. $-7.05M ÷ $-7.45M ≈ 0.95× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating cash flow | -7.05M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations |
| Capital spending | 109.54K USD | Payments to Acquire Property, Plant, and Equipment |
| Market cap | (m) | |
| Free cash flow | -7.16M USD | Net Cash Provided by (Used in) Operating Activities · Net Cash Provided by (Used in) Operating Activities, Continuing Operations · Payments to Acquire Property, Plant, and Equipment |
| Revenue | 9.47M USD | |
| Quarter-end shares | (m) | Common Stock, Shares, Outstanding |
| Net income | -7.45M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Free cash flow | FCF per share | Operating cash flow | Capital spending (USD) | Market cap (USD) | Revenue (USD) | Quarter-end shares (shares) | Net income (USD) | Price / FCF | FCF yield | FCF margin | Cash conversion |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $-7.16M | (m) | $-7.05M | $109.54K | (m) | $9.47M | (m) | $-7.45M | (m) | (m) | -75.63% | 0.95× |
| 2026-03-31 | $-7.57M | (m) | $-7.43M | $133.43K | (m) | $9.72M | (m) | $-6.64M | (m) | (m) | -77.84% | 1.12× |
| 2025-12-31 | $-6.26M | (m) | $-6.16M | $98.08K | (m) | $8.72M | (m) | $-6.83M | (m) | (m) | -71.81% | 0.90× |
| 2025-09-30 | $-2.92M | (m) | $-2.84M | $81.74K | (m) | $9.10M | (m) | $-3.61M | (m) | (m) | -32.09% | 0.79× |
| 2025-06-30 | $-4.09M | (m) | $-3.98M | $108.04K | (m) | $6.63M | (m) | $-5.34M | (m) | (m) | -61.65% | 0.75× |
| 2025-03-31 | (m) | (m) | $-4.88M | (m) | (m) | $5.76M | (m) | $-6.60M | (m) | (m) | (m) | 0.74× |
| 2024-12-31 | (m) | (m) | $-6.99M | (m) | (m) | $5.75M | (m) | $-7.19M | (m) | (m) | (m) | 0.97× |
| 2024-09-30 | $-11.13M | (m) | $-11.01M | $120.20K | (m) | $3.45M | (m) | $-12.32M | (m) | (m) | -322.39% | 0.89× |
| 2024-06-30 | $-11.39M | (m) | $-11.25M | $140.91K | (m) | $3.92M | (m) | $-12.10M | (m) | (m) | -290.34% | 0.93× |
| 2024-03-31 | $-12.09M | (m) | $-11.83M | $265.40K | (m) | $3.73M | (m) | $-12.80M | (m) | (m) | -324.50% | 0.92× |
| 2023-12-31 | $-13.61M | (m) | $-13.20M | $409.74K | (m) | $2.82M | (m) | $-13.47M | (m) | (m) | -483.53% | 0.98× |
| 2023-09-30 | $-13.27M | (m) | $-12.89M | $384.12K | (m) | $1.95M | (m) | $-11.86M | (m) | (m) | -679.71% | 1.09× |
| 2023-06-30 | $-9.36M | (m) | $-8.97M | $392.68K | (m) | $1.28M | (m) | $-10.10M | (m) | (m) | -731.48% | 0.89× |
| 2023-03-31 | $-8.97M | (m) | $-8.66M | $307.62K | (m) | $681.59K | (m) | $-9.39M | (m) | (m) | -1316.07% | 0.92× |
| 2022-12-31 | $-8.56M | (m) | $-8.33M | $225.25K | (m) | $252.00K | (m) | $-8.92M | (m) | (m) | -3395.99% | 0.93× |
| 2022-09-30 | $-7.79M | (m) | $-7.52M | $275.23K | (m) | $171.17K | (m) | $-10.00M | (m) | (m) | -4553.84% | 0.75× |
| 2022-06-30 | $-10.81M | (m) | $-10.57M | $244.15K | (m) | $150.72K | (m) | $-11.27M | (m) | (m) | -7172.92% | 0.94× |
| 2022-03-31 | $-10.44M | (m) | $-10.22M | $219.83K | (m) | $158.76K | (m) | $-11.46M | (m) | (m) | -6575.35% | 0.89× |
| 2021-12-31 | (m) | (m) | $-9.38M | (m) | (m) | $140.42K | (m) | $-10.80M | (m) | (m) | (m) | 0.87× |
| 2021-09-30 | $-8.67M | (m) | $-8.60M | $67.08K | (m) | $178.15K | (m) | $-9.95M | (m) | (m) | -4866.74% | 0.86× |
| 2021-06-30 | (m) | (m) | $-6.30M | (m) | (m) | (m) | (m) | $-7.87M | (m) | (m) | (m) | 0.80× |
| 2021-03-31 | (m) | (m) | $-5.23M | (m) | (m) | (m) | (m) | $-12.01M | (m) | (m) | (m) | 0.44× |
| 2020-12-31 | (m) | (m) | $-4.10M | (m) | (m) | (m) | (m) | $-10.96M | (m) | (m) | (m) | 0.37× |
| 2020-09-30 | $-3.55M | (m) | $-3.43M | $122.43K | (m) | (m) | (m) | $-13.64M | (m) | (m) | (m) | 0.25× |
| 2020-06-30 | $-4.85M | (m) | $-4.84M | $5.47K | (m) | (m) | (m) | $-14.43M | (m) | (m) | (m) | 0.34× |
| 2020-03-31 | $-5.33M | (m) | $-5.29M | $33.58K | (m) | (m) | (m) | $-9.20M | (m) | (m) | (m) | 0.58× |
| 2019-12-31 | (m) | (m) | $-5.92M | (m) | (m) | (m) | (m) | $-10.07M | (m) | (m) | (m) | 0.59× |
| 2019-09-30 | $-5.45M | (m) | $-5.40M | $58.35K | (m) | (m) | (m) | $-6.78M | (m) | (m) | (m) | 0.80× |
| 2019-06-30 | (m) | (m) | $-5.19M | (m) | (m) | (m) | (m) | $-7.94M | (m) | (m) | (m) | 0.65× |
| 2019-03-31 | (m) | (m) | $-4.21M | (m) | (m) | (m) | (m) | $-7.34M | (m) | (m) | (m) | 0.57× |
| 2018-12-31 | (m) | (m) | $-2.93M | (m) | (m) | (m) | (m) | $-6.49M | (m) | (m) | (m) | 0.45× |
| 2018-09-30 | (m) | (m) | $-2.83M | (m) | (m) | (m) | (m) | $-6.76M | (m) | (m) | (m) | 0.42× |
| 2018-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | (m) | $-2.11M | (m) | (m) | (m) | (m) | $-5.06M | (m) | (m) | (m) | 0.42× |
| 2017-09-30 | (m) | (m) | $-1.52M | (m) | (m) | (m) | (m) | $-3.52M | (m) | (m) | (m) | 0.43× |
| 2017-06-30 | (m) | (m) | $-926.06K | (m) | (m) | $0.00 | (m) | $-2.04M | (m) | (m) | (m) | 0.45× |
| 2017-03-31 | (m) | (m) | $-372.02K | (m) | (m) | $0.00 | (m) | $-768.39K | (m) | (m) | (m) | 0.48× |
| 2013-09-30 | (m) | (m) | $-23.88K | (m) | (m) | (m) | (m) | $-42.63K | (m) | (m) | (m) | 0.56× |
| 2013-06-30 | (m) | (m) | $-23.71K | (m) | (m) | (m) | (m) | $-42.11K | (m) | (m) | (m) | 0.56× |
| 2013-03-31 | (m) | (m) | $-11.20K | (m) | (m) | $1.18K | (m) | $-25.34K | (m) | (m) | (m) | 0.44× |
| 2012-12-31 | (m) | (m) | $-13.73K | (m) | (m) | $921.00 | (m) | $-27.60K | (m) | (m) | (m) | 0.50× |
| 2012-09-30 | (m) | (m) | $27.03K | (m) | (m) | $858.00 | (m) | $-28.05K | (m) | (m) | (m) | -0.96× |
| 2012-06-30 | (m) | (m) | $27.47K | (m) | (m) | (m) | (m) | $-27.62K | (m) | (m) | (m) | -0.99× |
| 2012-03-31 | (m) | (m) | $28.57K | (m) | (m) | $2.47K | (m) | $-26.49K | (m) | (m) | (m) | -1.08× |
| 2011-12-31 | (m) | (m) | $27.43K | (m) | (m) | $5.40K | (m) | $-27.60K | (m) | (m) | (m) | -0.99× |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | (m) | (m) | $-5.09K | (m) | (m) | $1.17K | (m) | $-6.04K | (m) | (m) | (m) | 0.84× |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sintx Technologies, Inc. (SINT) | United States | $0.012B | -1.10 |
| Picard Medical, Inc. (PMI) | United States | $0.011B | -0.01 |
| ALLURION TECHNOLOGIES, INC. (ALUR) | United States | $0.010B | |
| CERENOME, INC. (CNSY) | United States | $0.014B | |
| SeaStar Medical Holding Corp (ICU) | United States | $0.015B | -1.14 |
| Co-Diagnostics, Inc. (CODX) | United States | $0.007B | -0.32 |
| Modular Medical, Inc. (MODD) | United States | $0.018B | -0.88 |
| enVVeno Medical Corp (NVNO) | United States | $0.006B | -0.48 |
| Sonoma Pharmaceuticals, Inc. (SNOA) | United States | $0.006B | -2.59 |
| INTELLIGENT BIO SOLUTIONS INC. (INBS) | United States | $0.005B |